four marks against three
KLOW vs GLOW: What the Four-Peptide and Three-Peptide Blends Differ On
One peptide separates them. KLOW carries KPV; GLOW does not. Everything else about the contrast follows from that single mark.
The short version
KLOW vs GLOW comes down to one peptide. Both are research-only repair blends. GLOW is three peptides: GHK-Cu, BPC-157 and TB-500. KLOW is those same three plus a fourth — KPV.
KPV is the anti-inflammatory arm. It calms inflammation by switching down NF-kB, a master control for inflammatory genes. So the simple way to read the difference: KLOW adds a dedicated "calm the inflammation" component on top of the GLOW base. That is why users sometimes describe KLOW as feeling more anti-inflammatory.
One honest caveat covers both blends. Neither the four-peptide KLOW nor the three-peptide GLOW has ever been tested as a blend in a controlled study. Every difference below is a difference in composition and mechanism — not a head-to-head result.
The single structural difference: KPV
GLOW is a three-peptide blend: GHK-Cu (matrix and copper), BPC-157 (gut and tendon repair, angiogenesis) and TB-500 (wound closure). KLOW is the same three with KPV added [1].
KPV is the C-terminal tripeptide of alpha-MSH and the anti-inflammatory arm. Nanomolar KPV inhibits NF-kB and MAP-kinase signaling, lowers pro-inflammatory cytokines, and is carried into inflamed gut epithelium via the PepT1 transporter [2]. None of the GLOW three provides that cytokine-suppression node directly, so adding KPV is the one mechanistic axis on which the blends genuinely differ.
This is why community reports — anecdotal, not clinical — sometimes describe KLOW as feeling more anti-inflammatory than the KPV-free GLOW. It is a subjective comparison, not a head-to-head study.
What stays the same across both blends
The shared three carry the shared properties. GHK-Cu remains the mass-dominant matrix arm in both, with its copper load and its broad gene-expression footprint [7][8]. BPC-157 remains the angiogenic, connective-tissue and gut-repair arm in both [5][4][3]. TB-500 remains the cytoskeletal wound-closure arm — and the WADA-prohibited one — in both [6][10].
So the safety picture overlaps heavily: both blends carry the pro-angiogenesis caution, both carry the GHK-Cu copper load, and both implicate anti-doping rules through TB-500 [10][6][12]. KLOW adds KPV's immune-modulation consideration on top [2].
The same caveat applies to both: no blend study
Neither blend has been tested as a blend. No controlled study has compared KLOW against GLOW, KLOW against monotherapy, or GLOW against monotherapy [1]. The four-versus-three contrast is a contrast in composition and mechanism, drawn entirely from the single-component literature.
Both blends also share the pharmacokinetic-mismatch problem: their components clear at very different rates, so no single dose holds all of them at matched exposures [9]. Adding KPV to make four does not resolve that — it adds a fourth, fast-clearing tripeptide to the mismatch.
KLOW vs the Wolverine Blend
A second, lower-volume comparison sometimes raised: KLOW vs the Wolverine blend. The Wolverine blend is most commonly described as a two-peptide combination of BPC-157 and TB-500 — the repair-and-wound-closure pair without the GHK-Cu matrix arm and without KPV. KLOW, by contrast, is the four-peptide composition that adds both GHK-Cu (matrix, copper) and KPV (anti-inflammatory) on top of that BPC-157/TB-500 base [1].
As with GLOW, the contrast is one of composition and mechanism only. No controlled study has tested the Wolverine blend or KLOW as blends, and none has compared them; this is not a product recommendation.